The Lancet, ISSN 0140-6736, 06/2003, Volume 361, Issue 9374, p. 2092
Journal Article
Current Opinion in Pulmonary Medicine, ISSN 1070-5287, 05/2013, Volume 19, Issue 3, pp. 189 - 191
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9997, pp. 995 - 1007
Summary Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus...
Internal Medicine | DROMEDARY CAMELS | MEDICINE, GENERAL & INTERNAL | NEUTRALIZING ANTIBODIES | IMMUNE-RESPONSES | CLINICAL-ASPECTS | TO-HUMAN TRANSMISSION | MERS-COV | SYNDROME CORONAVIRUS INFECTION | CRITICALLY-ILL PATIENTS | FUNCTIONAL RECEPTOR | SAUDI-ARABIA | Epidemics | Coronavirus Infections - diagnosis | Humans | Middle Aged | Child, Preschool | Infant | Male | Coronavirus Infections - transmission | Middle East | Young Adult | Camelus - virology | Middle East Respiratory Syndrome Coronavirus - pathogenicity | Animals | Coronavirus Infections - epidemiology | Coronavirus Infections - therapy | Adolescent | Aged, 80 and over | Adult | Female | Aged | Child | Saudi Arabia | Acute respiratory distress syndrome | Comorbidity | Mortality | United Kingdom | Respiratory agents | Health aspects | Disease prevention | Viruses | Respiratory diseases | Prevention | Coronavirus | Treatment | Pathogenesis | Clinical | MERS-CoV | MERS | Middle East Respiratory Syndrome | Epidemiology | Public health | Virology
Internal Medicine | DROMEDARY CAMELS | MEDICINE, GENERAL & INTERNAL | NEUTRALIZING ANTIBODIES | IMMUNE-RESPONSES | CLINICAL-ASPECTS | TO-HUMAN TRANSMISSION | MERS-COV | SYNDROME CORONAVIRUS INFECTION | CRITICALLY-ILL PATIENTS | FUNCTIONAL RECEPTOR | SAUDI-ARABIA | Epidemics | Coronavirus Infections - diagnosis | Humans | Middle Aged | Child, Preschool | Infant | Male | Coronavirus Infections - transmission | Middle East | Young Adult | Camelus - virology | Middle East Respiratory Syndrome Coronavirus - pathogenicity | Animals | Coronavirus Infections - epidemiology | Coronavirus Infections - therapy | Adolescent | Aged, 80 and over | Adult | Female | Aged | Child | Saudi Arabia | Acute respiratory distress syndrome | Comorbidity | Mortality | United Kingdom | Respiratory agents | Health aspects | Disease prevention | Viruses | Respiratory diseases | Prevention | Coronavirus | Treatment | Pathogenesis | Clinical | MERS-CoV | MERS | Middle East Respiratory Syndrome | Epidemiology | Public health | Virology
Journal Article
The Lancet, ISSN 0140-6736, 07/2011, Volume 378, Issue 9785, pp. 57 - 72
Tuberculosis results in an estimated 1·7 million deaths each year and the worldwide number of new cases (more than 9 million) is higher than at any other time...
Journal Article
2003, ISBN 9781859846698, vi, 330
Book
2015, ISBN 1621820734, xii, 655
Book
Nature Reviews Drug Discovery, ISSN 1474-1776, 05/2013, Volume 12, Issue 5, pp. 388 - 404
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen,...
IN-VITRO | RESISTANT TUBERCULOSIS | ATP SYNTHASE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | EARLY BACTERICIDAL ACTIVITY | PULMONARY TUBERCULOSIS | BENZOTHIAZINONES | PHARMACOLOGY & PHARMACY | ANTIRETROVIRAL THERAPY | DOSE RIFAMPIN | MOXIFLOXACIN | KILL MYCOBACTERIUM-TUBERCULOSIS | Drug Evaluation, Preclinical - trends | Humans | Drug Discovery - trends | Clinical Trials as Topic | Mycobacterium tuberculosis - drug effects | Anti-Bacterial Agents - therapeutic use | Clinical Trials, Phase III as Topic | Drug Resistance, Multiple, Bacterial | Tuberculosis - drug therapy | Biomarkers | Research Design | Drug Combinations | Antitubercular Agents - therapeutic use | Clinical Trials, Phase II as Topic | Mycobacterium tuberculosis - genetics | Control | Tuberculosis | Demographic aspects | Causes of | Clinical trials | Antitubercular agents | Product development | Forecasts and trends | Research | Drug therapy
IN-VITRO | RESISTANT TUBERCULOSIS | ATP SYNTHASE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | EARLY BACTERICIDAL ACTIVITY | PULMONARY TUBERCULOSIS | BENZOTHIAZINONES | PHARMACOLOGY & PHARMACY | ANTIRETROVIRAL THERAPY | DOSE RIFAMPIN | MOXIFLOXACIN | KILL MYCOBACTERIUM-TUBERCULOSIS | Drug Evaluation, Preclinical - trends | Humans | Drug Discovery - trends | Clinical Trials as Topic | Mycobacterium tuberculosis - drug effects | Anti-Bacterial Agents - therapeutic use | Clinical Trials, Phase III as Topic | Drug Resistance, Multiple, Bacterial | Tuberculosis - drug therapy | Biomarkers | Research Design | Drug Combinations | Antitubercular Agents - therapeutic use | Clinical Trials, Phase II as Topic | Mycobacterium tuberculosis - genetics | Control | Tuberculosis | Demographic aspects | Causes of | Clinical trials | Antitubercular agents | Product development | Forecasts and trends | Research | Drug therapy
Journal Article
8.
Full Text
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Lancet Infectious Diseases, The, ISSN 1473-3099, 2010, Volume 10, Issue 9, pp. 621 - 629
Summary Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally thought to have high mortality rates. However, many cases can...
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | INVITRO ACTIVITY | TUBERCLE-BACILLI | INFECTIOUS DISEASES | EARLY BACTERICIDAL ACTIVITY | TREATMENT OUTCOMES | CROSS-RESISTANCE | MDR-TB | XDR-TB | CLAVULANIC ACID | RPOB MUTATIONS | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | INVITRO ACTIVITY | TUBERCLE-BACILLI | INFECTIOUS DISEASES | EARLY BACTERICIDAL ACTIVITY | TREATMENT OUTCOMES | CROSS-RESISTANCE | MDR-TB | XDR-TB | CLAVULANIC ACID | RPOB MUTATIONS | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents
Journal Article
2009, ISBN 1416039880, xxvi, 1014
This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage...
Tuberculosis | Treatment | Pathophysiology | Epidemiology
Tuberculosis | Treatment | Pathophysiology | Epidemiology
Book
New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 745 - 755
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 4, pp. 280 - 280
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 10, pp. 1011 - 1021
Summary Legionnaires' disease is an important cause of community-acquired and hospital-acquired pneumonia. Although uncommon, Legionnaires' disease continues...
Infectious Disease | LEGIONELLA-PNEUMOPHILA PNEUMONIA | INFECTIOUS DISEASES | COMMUNITY-ACQUIRED PNEUMONIA | HOSPITALIZED-PATIENTS | RISK-FACTORS | NEW-ZEALAND | PONTIAC FEVER | LONGBEACHAE SEROGROUP 1 | URINARY ANTIGEN | SEQUENCE TYPES | COOLING-TOWERS | Legionnaires' Disease - epidemiology | Global Health | Disease Outbreaks | Legionnaires' Disease - diagnosis | Legionnaires' Disease - transmission | Bacterial Typing Techniques | Humans | Virulence | Legionella pneumophila - classification | Legionella pneumophila - pathogenicity | Legionella pneumophila - isolation & purification | Legionnaires' Disease - therapy | Epidemics | Pneumonia | Hospitals | Bacterial pneumonia | Bacteria | Virulence (Microbiology) | Health aspects | Epidemiology | Public health | Cooling | Mortality | Fountains | Infections | Legionnaires disease | Patients | Resorts & spas | Surveillance | Aerosols | Fatalities
Infectious Disease | LEGIONELLA-PNEUMOPHILA PNEUMONIA | INFECTIOUS DISEASES | COMMUNITY-ACQUIRED PNEUMONIA | HOSPITALIZED-PATIENTS | RISK-FACTORS | NEW-ZEALAND | PONTIAC FEVER | LONGBEACHAE SEROGROUP 1 | URINARY ANTIGEN | SEQUENCE TYPES | COOLING-TOWERS | Legionnaires' Disease - epidemiology | Global Health | Disease Outbreaks | Legionnaires' Disease - diagnosis | Legionnaires' Disease - transmission | Bacterial Typing Techniques | Humans | Virulence | Legionella pneumophila - classification | Legionella pneumophila - pathogenicity | Legionella pneumophila - isolation & purification | Legionnaires' Disease - therapy | Epidemics | Pneumonia | Hospitals | Bacterial pneumonia | Bacteria | Virulence (Microbiology) | Health aspects | Epidemiology | Public health | Cooling | Mortality | Fountains | Infections | Legionnaires disease | Patients | Resorts & spas | Surveillance | Aerosols | Fatalities
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 9, pp. 752 - 761
Summary Background Middle East respiratory syndrome (MERS) is a new human disease caused by a novel coronavirus (CoV). Clinical data on MERS-CoV infections are...
Infectious Disease | CONFIRMATION | INFECTIOUS DISEASES | SARS | FEATURES | Age Factors | Humans | Middle Aged | Cross Infection - mortality | Male | Coronavirus Infections - mortality | Young Adult | Cross Infection - pathology | Coronavirus Infections - epidemiology | Aged, 80 and over | L-Lactate Dehydrogenase - analysis | Adult | Female | Cross Infection - virology | Odds Ratio | Child | Community-Acquired Infections - virology | Saudi Arabia - epidemiology | Fever - pathology | Coronavirus - isolation & purification | Community-Acquired Infections - mortality | Aspartate Aminotransferases - analysis | Diarrhea - virology | Thrombocytopenia - pathology | Community-Acquired Infections - pathology | Adolescent | Aged | Medicine, Experimental | Medical research | Arab countries | Epidemiology | Public health | Hospitals, Military
Infectious Disease | CONFIRMATION | INFECTIOUS DISEASES | SARS | FEATURES | Age Factors | Humans | Middle Aged | Cross Infection - mortality | Male | Coronavirus Infections - mortality | Young Adult | Cross Infection - pathology | Coronavirus Infections - epidemiology | Aged, 80 and over | L-Lactate Dehydrogenase - analysis | Adult | Female | Cross Infection - virology | Odds Ratio | Child | Community-Acquired Infections - virology | Saudi Arabia - epidemiology | Fever - pathology | Coronavirus - isolation & purification | Community-Acquired Infections - mortality | Aspartate Aminotransferases - analysis | Diarrhea - virology | Thrombocytopenia - pathology | Community-Acquired Infections - pathology | Adolescent | Aged | Medicine, Experimental | Medical research | Arab countries | Epidemiology | Public health | Hospitals, Military
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 4, pp. 327 - 340
Summary About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include...
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | TUBERCLE-BACILLI | INFECTIOUS DISEASES | IN-VITRO | LATENT TUBERCULOSIS | EARLY BACTERICIDAL ACTIVITY | MULTIDRUG-RESISTANT TUBERCULOSIS | PULMONARY TUBERCULOSIS | RANDOMIZED-TRIAL | ANTIRETROVIRAL THERAPY | 2 8-MONTH REGIMENS | Antitubercular Agents - adverse effects | Humans | Tuberculosis, Pulmonary - drug therapy | Clinical Trials as Topic | Drug Discovery | Medication Adherence | Immunotherapy | Biomarkers | Tuberculosis, Pulmonary - therapy | Drug Therapy, Combination | Research Design | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Drugs | Highly active antiretroviral therapy | Antiviral agents | Medical colleges | International cooperation | Antitubercular agents | Drug resistance | Drug approval | Patient compliance | Tuberculosis | Mortality | Clinical trials | Distribution costs | Drug dosages | Developing countries--LDCs | Public health | Index Medicus
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | TUBERCLE-BACILLI | INFECTIOUS DISEASES | IN-VITRO | LATENT TUBERCULOSIS | EARLY BACTERICIDAL ACTIVITY | MULTIDRUG-RESISTANT TUBERCULOSIS | PULMONARY TUBERCULOSIS | RANDOMIZED-TRIAL | ANTIRETROVIRAL THERAPY | 2 8-MONTH REGIMENS | Antitubercular Agents - adverse effects | Humans | Tuberculosis, Pulmonary - drug therapy | Clinical Trials as Topic | Drug Discovery | Medication Adherence | Immunotherapy | Biomarkers | Tuberculosis, Pulmonary - therapy | Drug Therapy, Combination | Research Design | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Drugs | Highly active antiretroviral therapy | Antiviral agents | Medical colleges | International cooperation | Antitubercular agents | Drug resistance | Drug approval | Patient compliance | Tuberculosis | Mortality | Clinical trials | Distribution costs | Drug dosages | Developing countries--LDCs | Public health | Index Medicus
Journal Article